
ABOUT ROCHE CUSTOMBIOTECH
From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech has supplied nucleotides and enzymes for mRNA production. We work with many pioneering mRNA companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast with market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring best quality, high performance within narrow tolerances, and reliable delivery.
Remaining at the front of this fast-paced therapeutic space hinges not only on ideas and implementation, but also on speed and quality. Your expertise is coming up with the idea and the implementation; as a long-standing global supplier, Roche CustomBiotech’s expertise in raw materials can help you accelerate development and ensure high quality mRNA. We help you strengthen your supply chain, ease transfers to manufacturing, secure continuous production, and create consistently high-quality products.
FEATURED INSIGHTS
-
Discover how to gain precise control over one of the most common and critical forms of protein modification for therapeutic benefit and stability.
-
From harsh chemicals to gentle enzymes: Explore the groundbreaking shift in nucleotide synthesis, making drug manufacturing cleaner, greener, and more efficient.
-
While organizations adapt to evolving safety and efficacy standards for mRNA, collaboration remains essential for navigating challenges like differing regional requirements, higher dosing needs, and analytical complexities.
-
Optimizing in vitro transcription (IVT) for mRNA is crucial to improving the stability of these molecules and enabling their large-scale production.
-
Advancements in purification, delivery mechanisms, and stability during storage and transport will enable the future of mRNA-based therapies.
-
Compared to traditional protein-based therapies, mRNA drugs exhibit unique pharmacokinetic profiles and can be rapidly developed, making overcoming their challenges critical for the industry.
-
Optimize your mRNA production by identifying an optimum set of conditions for the IVT reaction that produces high-quality mRNA in high yield using a design of experiment (DoE) approach.
-
Explore guidelines for the use of SP6 RNA Polymerase in mRNA synthesis and your mRNA production processes.
-
Learn about the problem of immunogenicity of mRNA, modified mRNA via in vitro transcription production, and choosing fit-for-purpose modified ribonucleotides.
-
Learn about tools to optimize the IVT reaction for enhanced mRNA yield, along with how factors such as magnesium ion and nucleotide concentrations significantly impact that IVT reaction performance.
-
Explore the advantages of mRNA technology, the process steps of large-scale mRNA production, and the effect of common contaminants on mRNA manufacturing.
CONTACT INFORMATION
Roche CustomBiotech
9115 Hague Road
Indianapolis, IN 46250
UNITED STATES
Phone: 1-800-428-5433
Contact: Laura Compton
SOLUTIONS

Roche CustomBiotech is committed to advancing cell and gene therapies by offering specialized solutions for manufacturing high-quality cell and gene therapeutics.

Streamline your biologics workflow, from initial development to final manufacturing, with comprehensive and high-quality solutions for consistency and efficiency.

Explore modern solutions for monitoring and analyzing cell culture in the pharmaceutical and biotech sectors.